Breaking News Instant updates and real-time market news.

AAPL

Apple

$116.05

1.99 (1.74%)

, SSNLF

Samsung

09:16
10/11/16
10/11
09:16
10/11/16
09:16

On The Fly: Pre-market Movers

HIGHER: Apple (AAPL), up 1.4% after rival Samsung (SSNLF) announced it will ask all carrier and retail partners globally to stop sales and exchanges of the Galaxy Note7... Radius Health (RDUS), up 4% after Ben Harrington's Betaville blog said that Shire (SHPG) is nearing a "multi-billion dollar" deal to acquire the company... Organovo (ONVO), up 5.8% after issuing FY17 revenue guidance that was above the consensus at its midpoint... Twitter (TWTR), up 3% after reports from Reuters and CNBC stated that Salesforce (CRM) remains in talks to possibly buy the company. DOWN AFTER EARNINGS: Alcoa (AA), down 4%. ALSO LOWER: Rent-A-Center (RCII), down 30% after pre-releasing worse than expected financial information for the third quarter, explaining that system performance issues and outages with its new point-of-sale system resulted in a larger than expected negative impact on Core sales... Illumina (ILMN), down 26.5% after the company reported preliminary Q3 revenue of $607M, below the Street's estimate near $628M... Lumentum (LITE), down 7% after being downgraded to Sell from Neutral at Goldman Sachs... Horizon Pharma (HZNP), down 7% after saying it sees FY16 adjusted net sales at low end of prior view and lowering its yearly adjusted EBITDA outlook... St. Jude Medical (STJ), down 2% after the company issued a field advisory related to premature battery depletion associated with lithium deposits in a subset of its ICD and CRT-D devices.

AAPL

Apple

$116.05

1.99 (1.74%)

SSNLF

Samsung

AA

Alcoa

RDUS

Radius Health

$52.10

0.5 (0.97%)

SHPG

Shire

$197.70

3.2 (1.65%)

ILMN

Illumina

$184.85

0.36 (0.20%)

STJ

St. Jude Medical

RCII

Rent-A-Center

$12.88

0.16 (1.26%)

ONVO

Organovo

$3.81

0.1 (2.70%)

TWTR

Twitter

CRM

Salesforce

HZNP

Horizon Pharma

$19.52

0.79 (4.22%)

  • 11

    Oct

  • 19

    Oct

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 01

    Nov

  • 06

    Nov

  • 14

    Nov

  • 30

    Nov

  • 14

    Dec

  • 13

    Mar

AAPL Apple
$116.05

1.99 (1.74%)

10/06/16
ADAM
10/06/16
NO CHANGE
Target $140
ADAM
Buy
Apple iPhone 7 demand remains healthy, says Canaccord
Canaccord analyst T. Michael Walkley said channel checks show demand for iPhone 7 remains healthy with an ongoing strong mix leading to higher selling prices. The analyst believes the iPhone 6 and iPhone 6s products enabled Apple to materially increase its market share and installed base of the premium tier smartphone market. Walkley reiterate his Buy rating and $140 price target on Apple shares.
10/10/16
DBAB
10/10/16
INITIATION
Target $90
DBAB
Sell
Deutsche sees Netflix takeover as unlikely, starts shares at Sell
Deutsche Bank analyst Bryan Kraft initiated shares of Netflix (NFLX) with a Sell rating and $90 price target. The stock closed Friday down 25c to $104.82. The risk/reward is unattractive as consensus expectations reflect an "optimistic case," Kraft tells investors in a research note. Market expectations appear too high through 2020, the analyst contends. He also expresses skepticism that Netflix will be acquired. The business is "too fully formed" and valued to be acquired by Disney (DIS) and Apple (AAPL), Kraft writes. He also sees Amazon.com (AMZN) as a competitive risk to Netflix.
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Apple has positive read through from Dialog results, says RBC Capital
After Dialog issued a positive preannouncement due to higher than expected Mobile Services revenue, RBC Capital analyst Amit Daryanani thinks that the Dialog results should comfort Apple investors heading into that company's September quarter results. The analyst notes that Apple accounts for 75%-80% of Dialog's revenue. He keeps a $125 price target and Outperform rating on Apple.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Apple average selling prices could beat expectations, says RBC Capital
RBC Capital analyst Amit Daryanani says that his analysis indicates that the average selling prices of Apple's iPhone 7 could significantly exceed Street expectations. Stronger demand for the "plus" model versus the last two years, along with the fact that Apple is charging a $120 premium for the "plus" model versus a $100 premium historically, should boost average selling prices, the analyst stated. He thinks that Apple's September quarter revenue could beat expectations by a "modest" amount, while the company's December quarter guidance could be "materially ahead of Street expectations." He keeps a $125 price target and Outperform rating on the stock.
SSNLF Samsung

04/26/16
NEED
04/26/16
NO CHANGE
NEED
Apple supply chain names to rebound, says Needham
Needham analyst Rajvindra Gill expects a rebound in the Apple (AAPL) supply chain names given its underperformance over the last 25 days and the relatively good quarterly results from Knowles (KN). Among the names, the analyst sees Cirrus Logic (CRUS) increasing its dollar content per unit about 40% for the iPhone 7 cycle, with possible upside of 80%-100% for the iPhone 7S in 2017 with the inclusion of adaptive noise cancellation. Knowles, which generated 25% of sales from Apple and less than 10% of sales from Samsung (SSNLF), posted better-than-expected results and guidance, the analyst tells investors in a research note.
04/13/16
ROTH
04/13/16
NO CHANGE
Target $2.6
ROTH
Buy
Digital Turbine estimates, price target reduced at Roth Capital
Roth Capital analyst Brian Alger reduced his estimates for Digital Turbine (APPS) and lowered his price target on the shares to $2.60 from $3, after the company quantified the miss that it had previewed last month. The shortfall was attributed to the slashed digital ad budget of a large advertising customer, Verizon (VZ) choosing to reduce the number of slots per device for much of the March quarter, and to Verizon Samsung S7's (SSNLF) that have yet to have Ignite software included, the analyst tells investors in a research note. Alger reiterates a Buy rating on Digital Turbine's shares, considering the depressed current valuation.
08/01/16
NEED
08/01/16
NO CHANGE
Target $65
NEED
Buy
Synaptics price target lowered to $65 from $88 at Needham
Needham analyst Rajvindra Gill lowered his price target for Synaptics (SYNA) to $65 from $88 on a lower earnings multiple as he remains uncertain on whether the company has secured the OLED DDIC for Apple's (AAPL) iPhone 8 versus an internal Samsung (SSNLF) solution. The analyst reiterates a Buy rating on Synaptics' shares, saying the company will remain one of the leaders in the display markets.
06/23/16
BFIN
06/23/16
NO CHANGE
BFIN
Fitbit faces 'fight of its life,' GoPro Karma delay a problem, says BlueFin
In an update on the wearable space, BlueFin analysts John Donovan and Steve Mullane make the case that Fitbit (FIT) is "in for the fight of its life" given mounting competition that is coming from Samsung (SSNLF), Apple (AAPL), Garmin (GRMN) and Under Armour (UA), adding that the sizable inventory of Alta and Blaze devices that it must deplete in this competitive environment puts Fitbit is in a "precarious position." The analyst add that Apple's watchOS improvements "further paint Fitbit into a corner," but noted that market data suggests consumers are looking for wearables under $200, which is in the "sweet spot" of Fitbit's portfolio. Weighing in on GoPro (GPRO), the analysts wonder if the Hero5 will be compelling enough to make consumers buy another camera and note that its upcoming Karma drone is very late to market and "facing daunting odds."
AA Alcoa

09/09/16
09/09/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Express (AXP) initiated with an Underweight at Atlantic Equities. 2. Alcoa (AA) initiated with a Neutral at Seaport Global. 3. Blue Buffalo Pet Products (BUFF) initiated with an Outperform at Oppenheimer. 4. Harley-Davidson (HOG) initiated with an Outperform at Bernstein. 5. Verifone (PAY) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/16
GHSC
09/09/16
INITIATION
Target $11
GHSC
Neutral
Alcoa initiated with a Neutral at Seaport Global
Seaport Global analyst Josh Sullivan initiated Alcoa with a Neutral and $11 price target.
05/23/16
BOFA
05/23/16
UPGRADE
BOFA
Buy
Alcoa upgraded to Buy from Neutral at BofA/Merrill
05/23/16
05/23/16
UPGRADE
Target $11

Buy
Alcoa upgraded to Buy from Neutral at BofA/Merrill
As previously reported, BofA/Merrill upgraded Alcoa to Buy from Neutral and raised its price target to $11 from $10.50. Analyst Timna Tanners said aluminum and alumina has become a lesser portion of Alcoa's earnings yet shares have become increasingly correlated to aluminum pricing while aerospace exposure now leaves it with an estimated 75% of its earnings levered to the segment. Tanners is confident in an upswing in aero-heavy downstream results and sees engine deliveries up 10% in 2016 and 18% in 2017. The analyst views the recent pullback in Alcoa shares as a buying opportunity given reduced commodity exposure and increased aero contribution.
RDUS Radius Health
$52.10

0.5 (0.97%)

09/21/16
HCWC
09/21/16
NO CHANGE
Target $71
HCWC
Buy
Radius Health price target raised to $71 from $55 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Radius Health to $71 saying results of the second generation transdermal patch in postmenopausal women are promising. ABL-TD patch could not only replace the anabolic drugs on the market, it could expand the market "significantly," Werther tells investors in a research note. She keeps a Buy rating on Radius.
08/15/16
JEFF
08/15/16
NO CHANGE
Target $46
JEFF
Hold
Radius Health price target raised to $46 from $37 at Jefferies
Jefferies analyst Eun Yang raised her price target for Radius Health to $46 but keeps a Hold rating on the shares. The analyst says her firm's physician poll shows convenient abalo-TD patch for osteoporosis, if successful, would increase abalo use by 25%-30%. Yang adds that while she isn't taking a "strong view" on recent M&A speculation, some of rumored buyers for Radius "don't seem a right fit."
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
08/04/16
08/04/16
DOWNGRADE

Sell
Followup: Radius Health downgraded to Sell from Hold at Maxim
As previously reported, Maxim downgraded Radius Health to Sell from Hold with a $24 price target. Analyst Jason McCarthy believes Radius shares are overvalued and continues to believe that Abaloparatide-SC will likely gain approval in 2017 in both the U.S. and Europe, but faces a mature Forteo market, competition from Biosimilar Forteo in 2018, and patients opting for alternative therapies.
SHPG Shire
$197.70

3.2 (1.65%)

08/31/16
JEFF
08/31/16
NO CHANGE
Target $262
JEFF
Buy
Shire making right moves in dry eye market, says Jefferies
After hosting meetings with management, Jefferies analyst David Steinberg believes Shire (SHPG) is making "all the right moves" to make its dry eye drug Xiidra a potential $2B peak product in the U.S. Shire's Xiidra is competing with Allergan's (AGN) $1.4B dry eye drug Restasis, Steinberg tells investors in a research note. The analyst does not think Shire will have any problem exceeding the drug's consensus sales forecast of $200M for next year. He keeps a Buy rating on the shares with a $262 price target.
08/03/16
LEER
08/03/16
NO CHANGE
Target $231
LEER
Outperform
Shire price target raised to $231 from $213 at Leerink
Leerink analyst Jason Gerberry raised his price target for Shire to $231 from $213 on valuation after the company reported "solid" Q2 results. The analyst reiterates an Outperform rating on the shares.
09/26/16
HSBC
09/26/16
DOWNGRADE
HSBC
Hold
Shire downgraded to Hold from Buy at HSBC
HSBC analyst Steve McGarry downgraded SHire to Hold saying valuation is no longer compelling.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
ILMN Illumina
$184.85

0.36 (0.20%)

09/12/16
SBSH
09/12/16
NO CHANGE
Target $190
SBSH
Buy
Illumina price target raised to $190 from $175 at Citi
Citi analyst Daniel Arias raised his price target for Illumina to $190 after traveling with the company's CFO Marc Stapley and investor relations head Rebecca Chambers. The analyst believes the business "can hold its own" in the second half of 2016 and that shares can move higher in 2017. He keeps a Buy rating on Illumina.
10/11/16
PIPR
10/11/16
NO CHANGE
Target $150
PIPR
Overweight
Illumina selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst William Quirk recommends using today's selloff in shares of Illumina as a buying opportunity. The stock traded down 24% last night after the company reported preliminary Q3 revenue of $607M, below the Street's $628.3M estimate. A lower number of HiSeq 2500/4000 installs as well as a HiSeq X Ten placement slip drove the revenue miss, Quirk tells investors in a research note. He notes, however, that his HiSeq X checks found the pipeline remains "very strong" at 95 systems, with a majority driven by the Chinese precision medicine program. He views $130 as a "technical floor" for the shares and dropped his price target for Illumina to $150 from $163. Quirk keeps an Overweight rating on the name.
10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
10/11/16
SBSH
10/11/16
DOWNGRADE
Target $140
SBSH
Neutral
Illumina downgraded to Neutral from Buy at Citi
Citi analyst Daniel Arias downgraded Illumina to Neutral saying last night's preannouncement marked the company's fourth miss in six quarters. "Forecasting capabilities have clearly diminished," Arias tells investors in a research note. He lowered his price target for the shares to $140 and thinks the stock could hit the $110-$120 range today. Illumina is trading down $48.59, or 26%, to $136.26 in the pre-market.
STJ St. Jude Medical

09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/08/16
PIPR
09/08/16
NO CHANGE
Target $82
PIPR
Neutral
Piper sees little reason to believe St. Jude deal will not close
Piper Jaffray analyst Brooks West says cybersecurity expert Mark Lanterman during a conference call yesterday refuted security claims by MedSec and Muddy Waters against St. Jude Medical's (STJ) pacemakers, defibrillators and Merlin monitoring system. Lanterman stated that there is "not much meat on the bone" to the MedSec claims and the quality of the analysis, West tells investors in a research note. He notes that Abbott (ABT) yesterday at a competitor conference earlier stated the St. Jude acquisition was progressing toward a close before year-end. The analyst sees little reason to believe the transaction will not close in the planned timeframe. West reiterates a Neutral rating on St. Jude.
08/29/16
FBCO
08/29/16
NO CHANGE
FBCO
St. Jude Medical can fix security deficiencies, says Credit Suisse
After speaking with "a developer of software used in drugs/devices" about Muddy Waters' security concerns regarding St. Jude's CRM system, Credit Suisse analyst Matthew Keeler says the consultant believes that the security deficiencies,can be fixed. According to the consultant, the deficiencies can be fixed using a five to ten person team working for about three months, Keeler stated. Keeler does not think that St. Jude's pending acquisition by Abbott (ABT) will be impacted by Muddy Waters' report. He keeps an $81 price target and Neutral rating on St. Jude.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
RCII Rent-A-Center
$12.88

0.16 (1.26%)

03/15/16
RAJA
03/15/16
UPGRADE
Target $21
RAJA
Strong Buy
Rent-A-Center upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Budd Bugatch upgraded Rent-A-Center to Strong Buy and raised his price target to $21 from $18. The analyst has increased conviction that forward estimates will prove to be too low given initiatives to improve the middle of the company's consolidated P&L, a strengthening balance sheet and deleveraging, and favorable risk/reward.
01/12/16
01/12/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Apple (AAPL) downgraded to Negative from Mixed at OTR Global... Asbury Automotive (ABG) downgraded to Hold from Buy at Craig-Hallum... AvalonBay (AVB) downgraded to Market Perform from Outperform at Cowen... BHP Billiton (BHP) downgraded to Underweight from Equal Weight at Barclays... Canadian Natural (CNQ) downgraded to Equal Weight from Overweight at Morgan Stanley... Cloud Peak (CLD) downgraded to Underweight from Equal Weight at Barclays... Comerica (CMA) downgraded to Underperform from Buy at BofA/Merrill... Concho Resources (CXO) downgraded to Hold from Buy at Jefferies... DDR Corp. (DDR) downgraded to Hold from Buy at Jefferies... DHT Holdings (DHT) downgraded to Neutral from Overweight at JPMorgan... Diageo (DEO) downgraded to Hold from Buy at Stifel... E-Trade (ETFC) downgraded to Buy from Conviction Buy at Goldman... EQT Corporation (EQT) downgraded to Hold from Buy at Jefferies... Encana (ECA) downgraded to Equal Weight from Overweight at Morgan Stanley... Essex Property Trust (ESS) downgraded to Market Perform from Outperform at Cowen... Euronav NV (EURN) downgraded to Neutral from Overweight at JPMorgan... F5 Networks (FFIV) downgraded to Hold from Buy at Deutsche Bank... Freeport McMoRan (FCX) downgraded to Hold from Buy at Jefferies... Great Plains Energy (GXP) downgraded to Neutral from Buy at BofA/Merrill... HCP (HCP) downgraded to Underperform from Hold at Jefferies... HeartWare (HTWR) downgraded to Neutral from Overweight at JPMorgan... InterContinental (IHG) downgraded to Neutral from Buy at Citi... Interactive Brokers (IBKR) downgraded to Sell from Neutral at Goldman... KNOT Offshore Partners (KNOP) downgraded to Neutral from Buy at Citi... LPL Financial (LPLA) downgraded to Sell from Neutral at Citi... Laclede (LG) downgraded to Underweight from Equal Weight at Morgan Stanley... Lazard (LAZ) downgraded to Neutral from Buy at Goldman... Liberty Property (LPT) downgraded to Market Perform from Outperform at Cowen... Marathon Oil (MRO) downgraded to Equal Weight from Overweight at Morgan Stanley... McKesson (MCK) downgraded to Market Perform from Outperform at Raymond James... Mead Johnson (MJN) downgraded to Neutral from Buy at Nomura... Medical Properties Trust (MPW) downgraded to Hold from Buy at Jefferies... NGL Energy Partners (NGL) downgraded to Hold from Buy at Stifel... Occidental Petroleum (OXY) downgraded to Hold from Buy at Jefferies... Omega Healthcare (OHI) downgraded to Hold from Buy at Jefferies... Patterson-UTI (PTEN) downgraded to Neutral from Overweight at Simmons... Peabody (BTU) downgraded to Underperform from Hold at Jefferies... Penn National (PENN) downgraded to Neutral at BofA/Merrill... Pinnacle West (PNW) downgraded to Underweight from Equal Weight at Morgan Stanley... Pioneer Energy (PES) downgraded to Neutral from Overweight at Simmons... Progressive Waste (BIN) downgraded to In-Line from Outperform at Imperial Capital... Prosperity Bancshares (PB) downgraded to Underperform from Neutral at BofA/Merrill... Raymond James (RJF) downgraded to Neutral from Buy at Citi... Rent-A-Center (RCII) downgraded to Hold from Buy at BB&T... Roadrunner (RRTS) downgraded to Peer Perform from Outperform at Wolfe Research... Rose Rock Midstream (RRMS) downgraded to Equalweight from Overweight at Capital One... Rouse Properties (RSE) downgraded to Underperform from Neutral at BofA/Merrill... SABMiller (SBMRY) downgraded to Hold from Buy at Stifel ... Scientific Games (SGMS) downgraded to Underperform from Neutral at BofA/Merrill... Southern Copper (SCCO) downgraded to Equal Weight from Overweight at Barclays... Synergy Resources (SYRG) downgraded to Equal Weight from Overweight at Stephens... Taubman Centers (TCO) downgraded to Underperform from Hold at Jefferies... Teekay Tankers (TNK) downgraded to Underweight from Overweight at JPMorgan... Telenor (TELNY) downgraded to Underweight from Overweight at JPMorgan... UDR, Inc. (UDR) downgraded to Market Perform from Outperform at Cowen... Vedanta Resources (VDNRF) downgraded to Underperform from Hold at Jefferies... Western Gas Partners (WES) downgraded to Neutral from Buy at BofA/Merrill... Whiting Petroleum (WLL) downgraded to Underweight from Equal Weight at Morgan Stanley... Zurich Insurance (ZURVY) downgraded to Underweight from Neutral at JPMorgan.
05/23/16
05/23/16
INITIATION
Target $27

Buy
Rent-A-Center initiated with a Buy at Topeka
Target $27.
01/12/16
01/12/16
DOWNGRADE

Hold
Rent-A-Center downgraded on rent to own trends at BB&T
As noted earlier, BB&T downgraded Rent-A-Center to Hold from Buy. The firm says that the company is being hurt by the transition of rent-to-own business from brick and mortar to virtual. The firm thinks the company may have to cut its dividend.
ONVO Organovo
$3.81

0.1 (2.70%)

08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
TWTR Twitter

10/11/16
EVER
10/11/16
UPGRADE
Target $17
EVER
Hold
Twitter upgraded to Hold from Sell at Evercore ISI
Evercore ISI analyst Ken Sena upgraded Twitter (TWTR) to Neutral citing the recent pullback in the shares. The analyst notes that the selloff "from a stalled sale process" has put the stock more in-line with his unchanged price target of $17. Sena thinks Twitter's guidance for Q3 "may prove sufficiently conservative."
10/07/16
ADAM
10/07/16
NO CHANGE
Target $95
ADAM
Buy
Salesforce worthy of investor consideration at current levels, says Canaccord
Canaccord analyst Richard Davis came away from the Salesforce (CRM) Dreamforce week more enthused about the company's outlook. The analyst noted the company is growing its revenues 3.5 times faster than it legacy peers. Davis noted the company's CEO said they are very disciplined on price when it comes to acquisitions and believes that they would not be interested in Twitter (TWTR) at its rumored asking price of $28 per share. Davis reiterated his Buy rating and $95 price target on Salesforce shares.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $95
JPMS
Overweight
JPMorgan sees 'opportune entry point' for Salesforce
JPMorgan analyst Mark Murphy believes shares of Salesforce (CRM) are at an "'opportune entry point" following the recent selloff. The pullback has been driven by a "slightly soft" Q2 and concerns about a potentially expensive acquisition of Twitter (TWTR), Murphy tells investors in a research note. After speaking to industry contacts at Dreamforce, the analyst sees a path for the "overhangs to fade" with a "better pace of business in Q3/Q4" as well as the eventual fading of the Twitter discussion. Murphy reiterates an Overweight rating on Salesforce with a $95 price target in a research note titled "The Most Valuable Cloud Asset Is Undeservedly Undervalued."
10/11/16
DBAB
10/11/16
NO CHANGE
Target $22
DBAB
Buy
Twitter guidance could meet, exceed estimates, says Deutsche Bank
Deutsche Bank analyst Ross Sandler says that for the first time in a year, Twitter's guidance could meet or exceed consensus expectations. The analyst sees a good risk/reward profile for shares into the company's Q3 results. He notes that his channel checks point to a "high-end of the range" revenue with "slightly up" monthly active users for Q3. Twitter's NFL live video project "has been by all accounts a smashing success," Sandler tells investors in a research note. He keep a Buy rating on Twitter with a $22 price target.
CRM Salesforce

10/06/16
BMOC
10/06/16
NO CHANGE
BMOC
Twitter acquisition would hurt Salesforce, says BMO Capital
BMO Capital analyst Keith Bachman says that an acquisition of Twitter (TWTR) by Salesforce (CRM) would " offer little strategic fit, would slow revenue growth and would be dilutive to (free cash flow) margins." Bachman thinks that the deal would cause Salesforce's stock to drop significantly,. and he says that the company's stock would be worth $65 if it pulls the trigger on Twitter. The analyst says that Salesforce's current valuation is attractive if it does not buy Twitter. He keeps an $86 price target and Outperform rating on Salesforce.
10/07/16
PIPR
10/07/16
NO CHANGE
Target $100
PIPR
Overweight
Piper sees 'clouds parting' on Salesforce valuation
Salesforce CEO Marc Benioff mostly calmed nerves over a potential Twitter (TWTR) acquisition by saying at the company's analyst day, "While we look at everything, we pass on almost everything," Piper Jaffray analyst Alex Zukin tells investors in a research note. The comment does not completely take a deal for Twitter off the table, but the probability of a transformational acquisition is now "dramatically lower," Zukin contends. As such, the analyst feels the "clouds are parting" on Salesforce's valuation "with sunshine ahead." Zukin believes the company has a "clear line of sight" to $10B in revenue in FY17. He keeps an Overweight rating on the shares with a $100 price target. Salesforce closed yesterday up $2.84, or 4%, to $71.26.
HZNP Horizon Pharma
$19.52

0.79 (4.22%)

08/02/16
BMOC
08/02/16
NO CHANGE
BMOC
Outperform
Horizon Pharma scored 'important win' with CVS, says BMO Capital
BMO Capital analyst Gary Nachman said Horizon Pharma (HZNP) securing covered status for Duexis and Vimovo with CVS/Caremark (CVS) is an "important win" for the drugmaker that demonstrates it is improving its execution on the managed care front. While Express Scripts (ESRX) still has Duexis and Vimovo on its exclusion list for 2017, Horizon indicated that it is still in discussions that have been "constructive," noted Nachman, who keeps an Outperform rating on Horizon shares.
09/30/16
JMPS
09/30/16
NO CHANGE
JMPS
Horizon Pharma patent loss immaterial, says JMP Securities
After the U.S. Patent and Trademark Office ruled that Horizon Pharma's '215 patent for Ravicti is unpatentable, JMP Securities analyst Donald Ellis says the news is not material. He says that Ravicti still has orphan drug exclusivity until 2020, and that the company has five other patents on the drug that will last until 2032. He recommends buying Horizon on any weakness.
09/13/16
BMUR
09/13/16
NO CHANGE
Target $32
BMUR
Buy
Horizon Pharma acquisition a positive, says Brean Capital
Brean Capital analyst Difei Yang said she is positive on Horizon Pharma's (HZNP) deal for Raptor Pharmaceuticals (RPTP). The analyst cited Horizon executing on its transformative strategy into an orphan disease company, the reasonable price paid for the company, and the moderate growth opportunities for synergies between the two. Yang reiterated her Buy rating and raised her price target to $32 from $30 on Horizon Pharma shares.
10/03/16
BMOC
10/03/16
NO CHANGE
BMOC
Horizon Pharma added to US Small Cap Fundamental List at BMO Capital

TODAY'S FREE FLY STORIES

CNX

CONSOL

$21.30

-0.48 (-2.20%)

, CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

15:02
12/10/16
12/10
15:02
12/10/16
15:02
Conference/Events
CONE Midstream participates in an analyst and investor day »

Management participates…

CNX

CONSOL

$21.30

-0.48 (-2.20%)

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

, CNX

CONSOL

$21.30

-0.48 (-2.20%)

14:59
12/10/16
12/10
14:59
12/10/16
14:59
Conference/Events
CONSOL to host analyst and investor day »

Analyst and Investor Day…

CNNX

CONE Midstream

$21.33

-0.15 (-0.70%)

CNX

CONSOL

$21.30

-0.48 (-2.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BG

Bunge

$73.36

-0.04 (-0.05%)

14:54
12/10/16
12/10
14:54
12/10/16
14:54
Conference/Events
Bunge to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

14:50
12/10/16
12/10
14:50
12/10/16
14:50
Conference/Events
AMD to host Summit Ridge a "Zen"-based CPU at New Horizon »

President & CEO Su…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$50.76

0.61 (1.22%)

14:41
12/10/16
12/10
14:41
12/10/16
14:41
Conference/Events
Arthur J. Gallagher to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

NYT

New York Times

$14.10

0.15 (1.08%)

14:34
12/10/16
12/10
14:34
12/10/16
14:34
Conference/Events
Detroit Economic Club to hold a luncheon meeting »

Mark Thompson, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$27.16

0.89 (3.39%)

14:28
12/10/16
12/10
14:28
12/10/16
14:28
Conference/Events
AstraZeneca has a luncheon meeting with Philadelphia Securities Association »

Luncheon Meeting being…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Feb

CASC

Cascadian Therapeutics

$5.65

-0.03 (-0.53%)

, GHDX

Genomic Health

$30.81

-0.17 (-0.55%)

04:55
12/10/16
12/10
04:55
12/10/16
04:55
Conference/Events
UT Health Science Center to hold a symposium »

2016 San Antonio Breast…

CASC

Cascadian Therapeutics

$5.65

-0.03 (-0.53%)

GHDX

Genomic Health

$30.81

-0.17 (-0.55%)

MYGN

Myriad Genetics

$17.40

0.41 (2.41%)

RDUS

Radius Health

$43.94

-3.13 (-6.65%)

OCX

OncoCyte

$6.15

0.05 (0.82%)

ABBV

AbbVie

$61.54

0.64 (1.05%)

BAYRY

Bayer

$100.04

1.14 (1.15%)

CELG

Celgene

$113.47

0.41 (0.36%)

CLDX

Celldex

$3.75

0.01 (0.27%)

DNA

Bought by RHHBY

HRTX

Heron Therapeutics

$14.90

-0.55 (-3.56%)

PFE

Pfizer

$31.70

0.76 (2.46%)

PBYI

Puma Biotechnology

$36.50

0.05 (0.14%)

TSRO

TESARO

$129.97

-1.57 (-1.19%)

NSTG

NanoString

$21.79

-0.35 (-1.58%)

NVS

Novartis

$69.74

2.15 (3.18%)

NVTA

Invitae

$7.24

0.28 (4.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 11

    Jan

BBSI

Barrett Business

$62.30

1.85 (3.06%)

, BREW

Craft Brew

$16.65

0.45 (2.78%)

04:55
12/10/16
12/10
04:55
12/10/16
04:55
Conference/Events
Roth Capital to hold a conference »

5th Annual ROTH Utah…

BBSI

Barrett Business

$62.30

1.85 (3.06%)

BREW

Craft Brew

$16.65

0.45 (2.78%)

CHKE

Cherokee

$11.10

-0.35 (-3.06%)

DFBG

Differential Brands

$3.20

0.25 (8.47%)

DLA

Delta Apparel

$20.77

-0.39 (-1.84%)

ESCA

Escalade

$13.65

-0.15 (-1.09%)

FLKS

Flex Pharma

$6.29

-0.01 (-0.16%)

KONA

Kona Grill

$12.75

0.05 (0.39%)

LNDC

Landec

$15.05

-0.25 (-1.63%)

MEET

MeetMe

$5.63

0.16 (2.93%)

MITK

Mitek Systems

$6.50

0.35 (5.69%)

MB

MINDBODY

$20.70

-0.25 (-1.19%)

OSIS

OSI Systems

$78.17

1.22 (1.59%)

PLNT

Planet Fitness

$21.01

-0.07 (-0.33%)

ROX

Castle Brands

$0.75

0.0309 (4.30%)

PRTS

U.S. Auto Parts

$3.33

0.09 (2.78%)

RSYS

RadiSys

$4.77

0.11 (2.36%)

SWHC

Smith & Wesson

$21.07

-0.16 (-0.75%)

VSTO

Vista Outdoor

$38.62

-1.24 (-3.11%)

WMAR

West Marine

$9.41

0.13 (1.40%)

ZAGG

ZAGG

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 13

    Dec

  • 13

    Dec

  • 09

    Jan

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

, CSCO

Cisco

$30.06

0.11 (0.37%)

18:32
12/09/16
12/09
18:32
12/09/16
18:32
Hot Stocks
Arista Networks favored in ITC initial determination on four of six patents »

Arista Networks (ANET)…

ANET

Arista Networks

$94.41

-1.35 (-1.41%)

CSCO

Cisco

$30.06

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 12

    Dec

  • 12

    Dec

TKTDY

Takata Corporation

$10.70

0.05 (0.47%)

18:22
12/09/16
12/09
18:22
12/09/16
18:22
Periodicals
U.S. DOT looks to accelerate pace of Takata air bag replacements, Reuters says »

The U.S. Department of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DV

DeVry

$31.90

0.9 (2.90%)

18:17
12/09/16
12/09
18:17
12/09/16
18:17
Hot Stocks
Breaking Hot Stocks news story on DeVry »

International Value…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

18:10
12/09/16
12/09
18:10
12/09/16
18:10
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Cornerstone OnDemand has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$0.12

-0.0014 (-1.17%)

18:03
12/09/16
12/09
18:03
12/09/16
18:03
Hot Stocks
NYSE MKT says CEL-SCI noncompliant with certain listing requirements »

CEL-SCI reported on a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$89.00

0.68 (0.77%)

18:01
12/09/16
12/09
18:01
12/09/16
18:01
Periodicals
Exxon CEO Tillerson emerges as top candidate for secretary of state, WSJ says »

Exxon Mobil CEO Rex…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FUL

H.B. Fuller

$50.36

0.05 (0.10%)

17:58
12/09/16
12/09
17:58
12/09/16
17:58
Hot Stocks
H.B. Fuller announces restructuring, to eliminate, relocate 220 positions »

H.B. Fuller has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIIB

Biogen

$287.77

-1.77 (-0.61%)

17:53
12/09/16
12/09
17:53
12/09/16
17:53
Periodicals
Biogen looks like a bargain, Barron's reports »

Biogen trades at just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$40.40

0.63 (1.58%)

17:42
12/09/16
12/09
17:42
12/09/16
17:42
Periodicals
Sanofi to lay off 20% of U.S. diabetes, cardiovascular staff, Bloomberg says »

The layoffs include parts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

CSOD

Cornerstone OnDemand

$39.10

-0.11 (-0.28%)

17:38
12/09/16
12/09
17:38
12/09/16
17:38
Periodicals
Cornerstone OnDemand considers sale amid activist pressure, Bloomberg reports »

Investor Praesidium said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TACO

Del Taco

$14.75

-0.39 (-2.58%)

17:34
12/09/16
12/09
17:34
12/09/16
17:34
Hot Stocks
Breaking Hot Stocks news story on Del Taco »

PW Acquisitions cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 09

    Dec

UNVR

Univar

$26.36

0.54 (2.09%)

, BXLT

Baxalta

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Univar names Eric Foster chief information officer »

Univar (UNVR) named Eric…

UNVR

Univar

$26.36

0.54 (2.09%)

BXLT

Baxalta

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PARN

Parnell

$1.42

-0.0031 (-0.22%)

17:30
12/09/16
12/09
17:30
12/09/16
17:30
Hot Stocks
Breaking Hot Stocks news story on Parnell 

Parnell trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$20.81

0.2 (0.97%)

, NVRO

Nevro

$76.38

-1.88 (-2.40%)

17:24
12/09/16
12/09
17:24
12/09/16
17:24
Hot Stocks
Boston Scientific files patent infringement suit against Nevro »

Nevro (NVRO) announced…

BSX

Boston Scientific

$20.81

0.2 (0.97%)

NVRO

Nevro

$76.38

-1.88 (-2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

RTN

Raytheon

$146.30

0.14 (0.10%)

17:21
12/09/16
12/09
17:21
12/09/16
17:21
Hot Stocks
Raytheon awarded $101.9M government contract »

Raytheon Co., Goleta,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$8.77

-0.16 (-1.79%)

17:18
12/09/16
12/09
17:18
12/09/16
17:18
Hot Stocks
CEMEX receives subpoena from SEC regarding Foreign Corrupt Practices Act »

On December 9, 2016,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.